# Prosit Sole

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prosit-sole

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.prositsole.com
- Latest round: Series B (Feb 7, 2021)
- Investors on record: 2

## About

Established in 2013 and based in Beijing, China, Prosit Sole is a biotechnology company that focuses on the innovation of protein therapeutics. It has set up an R&D Center and manufacturing facility in Hebei, and a Clinical Research Center in Seattle. The company's founder and CEO, Hongyu Liu, graduated from the University of Houston and served as head of protein production in Novo Nordisk. The R&D management team has over 25 years of pharmaceutical industrial experience. In February 2021, Prosit Sole raised series B funding led by new investor Longmen Capital.

The company is committed to developing innovative protein drugs. It has developed the Prositsole Protein Optimize Platform (P-POP) that contains the function of drug screening, cell banking, animal disease models, etc. There are already 6 innovative drugs in the company's product pipeline for treating rare diseases.

## Funding rounds

- Series B, Feb 7, 2021 — Zhuhai Longmen Capital Management
- Series A, Nov 23, 2017 — Rotating Boulder Fund

## Investors

- Rotating Boulder Fund (https://capitalatlas.ai/funds/rotating-boulder-fund) — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series B